1
|
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, Lapham H, Head N, Stovin C, Patel V, Clarke BD, Nagra D, Alveyn E, Adas MA, Bechman K, de la Puente MA, Ellis B, Byrne C, Patel R, Rutherford AI, Cantle F, Norton S, Roddy E, Hudson J, Cope AP, Galloway JB. Implementing treat-to-target urate-lowering therapy during hospitalisations for gout flares. Rheumatology (Oxford) 2023:kead574. [PMID: 37929968 DOI: 10.1093/rheumatology/kead574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/25/2023] [Accepted: 08/13/2023] [Indexed: 11/07/2023] Open
Abstract
OBJECTIVES To evaluate a strategy designed to optimise care and increase uptake of urate-lowering therapy (ULT) during hospitalisations for gout flares. METHODS We conducted a prospective cohort study to evaluate a strategy that combined optimal in-hospital gout management with a nurse-led, follow-up appointment, followed by handover to primary care. Outcomes, including ULT initiation, urate target attainment, and re-hospitalisation rates, were compared between patients hospitalised for flares in the 12 months post-implementation and a retrospective cohort of hospitalised patients from 12 months pre-implementation. RESULTS 119 and 108 patients, respectively, were hospitalised for gout flares in the 12 months pre- and post-implementation. For patients with 6-month follow-up data available (n = 94 and n = 97, respectively), the proportion newly initiated on ULT increased from 49.2% pre-implementation to 92.3% post-implementation (age/sex-adjusted odds ratio (aOR) 11.5; 95% confidence interval (CI) 4.36-30.5; p < 0.001). After implementation, more patients achieved a serum urate ≤360 micromol/L within 6 months of discharge (10.6% pre-implementation vs. 26.8% post-implementation; aOR 3.04; 95% CI 1.36-6.78; p = 0.007). The proportion of patients re-hospitalised for flares was 14.9% pre-implementation vs. 9.3% post-implementation (aOR 0.53, 95% CI 0.22 to 1.32; p = 0.18). CONCLUSION Over 90% of patients were initiated on ULT after implementing a strategy to optimise hospital gout care. Despite increased initiation of ULT during flares, recurrent hospitalisations were not more frequent following implementation. Significant relative improvements in urate target attainment were observed post-implementation; however, for the majority of hospitalised gout patients to achieve urate targets, closer primary-secondary care integration is still needed.
Collapse
Affiliation(s)
- Mark D Russell
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Louise Ameyaw-Kyeremeh
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Flora Dell'Accio
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Heather Lapham
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Natalie Head
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Christopher Stovin
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Vishit Patel
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Benjamin D Clarke
- Benjamin Clarke, Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Deepak Nagra
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Edward Alveyn
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Maryam A Adas
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Katie Bechman
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - María A de la Puente
- Department of Psychology, Health Psychology Section, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, London, United Kingdom
| | - Benjamin Ellis
- Department of Rheumatology, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom
| | - Corrine Byrne
- Pharmacy Department, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Rina Patel
- Pharmacy Department, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Andrew I Rutherford
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Fleur Cantle
- Department of Emergency Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom
| | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - Edward Roddy
- School of Medicine, Keele University, Keele, United Kingdom
| | - Joanna Hudson
- Department of Psychology, Health Psychology Section, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, London, United Kingdom
| |
Collapse
|
2
|
Russell MD, Massey J, Roddy E, MacKenna B, Bacon S, Goldacre B, Andrews CD, Hickman G, Mehrkar A, Mahto A, Rutherford AI, Patel S, Adas MA, Alveyn E, Nagra D, Bechman K, Ledingham JM, Hudson J, Norton S, Cope AP, Galloway JB. Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY. Lancet Rheumatol 2023; 5:e622-e632. [PMID: 38251486 DOI: 10.1016/s2665-9913(23)00206-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/07/2023] [Accepted: 07/24/2023] [Indexed: 01/23/2024]
Abstract
BACKGROUND Gout is the most prevalent inflammatory arthritis, yet one of the worst managed. Our objective was to assess how the COVID-19 pandemic impacted incidence and quality of care for people with gout in England, UK. METHODS With the approval of National Health Service England, we did a population-level cohort study using primary care and hospital electronic health record data for 17·9 million adults registered with general practices using TPP health record software, via the OpenSAFELY platform. The study period was from March 1, 2015, to Feb 28, 2023. Individuals aged 18-110 years were defined as having incident gout if they were assigned index diagnostic codes for gout, were registered with TPP practices in England for at least 12 months before diagnosis, did not receive prescriptions for urate-lowering therapy more than 30 days before diagnosis, and had not been admitted to hospital or attended an emergency department for gout flares more than 30 days before diagnosis. Outcomes assessed were incidence and prevalence of people with recorded gout diagnoses, incidence of gout hospitalisations, initiation of urate-lowering therapy, and attainment of serum urate targets (≤360 μmol/L). FINDINGS From a reference population of 17 865 145 adults, 246 695 individuals were diagnosed with incident gout. The mean age of individuals with incident gout was 61·3 years (SD 16·2). 66 265 (26·9%) of 246 695 individuals were female, 180 430 (73·1%) were male, and 189 035 (90·9%) of 208 050 individuals with available ethnicity data were White. Incident gout diagnoses decreased by 30·9% in the year beginning March, 2020, compared with the preceding year (1·23 diagnoses vs 1·78 diagnoses per 1000 adults). Gout prevalence was 3·07% in 2015-16, and 3·21% in 2022-23. Gout hospitalisations decreased by 30·1% in the year commencing March, 2020, compared with the preceding year (9·6 admissions vs 13·7 admissions per 100 000 adults). Of 228 095 people with incident gout and available follow-up, 66 560 (29·2%) were prescribed urate-lowering therapy within 6 months. Of 65 305 individuals who initiated urate-lowering therapy with available follow-up, 16 790 (25·7%) attained a serum urate concentration of 360 μmol/L or less within 6 months of urate-lowering therapy initiation. In interrupted time-series analyses, urate-lowering therapy prescribing improved modestly during the pandemic, compared with pre-pandemic, whereas urate target attainment was similar. INTERPRETATION Using gout as an exemplar disease, we showed the complexity of how health care was impacted during the COVID-19 pandemic. We observed a reduction in gout diagnoses but no effect on treatment metrics. We showed how country-wide, routinely collected data can be used to map disease epidemiology and monitor care quality. FUNDING None.
Collapse
Affiliation(s)
- Mark D Russell
- Centre for Rheumatic Diseases, King's College London, London, UK.
| | - Jon Massey
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | | | - Brian MacKenna
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Seb Bacon
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Ben Goldacre
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Colm D Andrews
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - George Hickman
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Amir Mehrkar
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Arti Mahto
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK
| | - Andrew I Rutherford
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK
| | - Samir Patel
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Maryam A Adas
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Edward Alveyn
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Deepak Nagra
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Katie Bechman
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Joanna M Ledingham
- Rheumatology Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
| | - Joanna Hudson
- Department of Psychology, Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK
| |
Collapse
|
3
|
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis 2023; 82:1059-1067. [PMID: 37247942 PMCID: PMC10359573 DOI: 10.1136/ard-2023-224049] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 04/25/2023] [Indexed: 05/31/2023]
Abstract
OBJECTIVES To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. METHODS Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) compared with placebo, TNFi or methotrexate, in adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy between JAKi and comparators. Bias was assessed using the Cochrane Risk of Bias-2 tool. RESULTS In 62 eligible RCTs and 16 LTE studies, there were 82 366 person-years of exposure to JAKi, 2924 to placebo, 7909 to TNFi and 1074 to methotrexate. The overall malignancy incidence rate was 1.15 per 100 person-years in RCTs, and 1.26 per 100 person-years across combined RCT and LTE data. In network meta-analyses, the incidence of all malignancies including non-melanomatous skin cancers (NMSCs) was not significantly different between JAKi and placebo (IRR 0.71; 95% CI 0.44 to 1.15) or between JAKi and methotrexate (IRR 0.77; 95% CI 0.35 to 1.68). Compared with TNFi, however, JAKi were associated with an increased incidence of malignancy (IRR 1.50; 95% CI 1.16 to 1.94). Findings were consistent when analysing NMSC only and when analysing combined RCT/LTE data. CONCLUSIONS JAKi were associated with a higher incidence of malignancy compared with TNFi but not placebo or methotrexate. Cancers were rare events in all comparisons. PROSPERO REGISTRATION NUMBER CRD42022362630.
Collapse
Affiliation(s)
- Mark D Russell
- Centre for Rheumatic Diseases, King's College London, London, UK
| | | | - Edward Alveyn
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Olukemi Adeyemi
- Centre for Rheumatic Diseases, King's College London, London, UK
| | | | - Vishit Patel
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Maryam A Adas
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Fabiola Atzeni
- Rheumatology Unit, University of Messina, Messina, Italy
| | - Kenrick K H Ng
- Department of Medical Oncology, University College London, London, UK
| | | | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK
| |
Collapse
|
4
|
Russell MD, Roddy E, Rutherford AI, Ellis B, Norton S, Douiri A, Gulliford MC, Cope AP, Galloway JB. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England. Rheumatology (Oxford) 2023; 62:2426-2434. [PMID: 36355461 PMCID: PMC10321109 DOI: 10.1093/rheumatology/keac638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 11/03/2022] [Indexed: 07/20/2023] Open
Abstract
OBJECTIVE To investigate associations between treat-to-target urate-lowering therapy (ULT) and hospitalizations for gout. METHODS Using linked Clinical Practice Research Datalink and NHS Digital Hospital Episode Statistics data, we described the incidence and timing of hospitalizations for flares in people with index gout diagnoses in England from 2004-2020. Using Cox proportional hazards and propensity models, we investigated associations between ULT initiation, serum urate target attainment, colchicine prophylaxis, and the risk of hospitalizations for gout. RESULTS Of 292 270 people with incident gout, 7719 (2.64%) had one or more hospitalizations for gout, with an incidence rate of 4.64 hospitalizations per 1000 person-years (95% CI 4.54, 4.73). There was an associated increased risk of hospitalizations within the first 6 months after ULT initiation, when compared with people who did not initiate ULT [adjusted Hazard Ratio (aHR) 4.54; 95% CI 3.70, 5.58; P < 0.001]. Hospitalizations did not differ significantly between people prescribed vs not prescribed colchicine prophylaxis in fully adjusted models. From 12 months after initiation, ULT associated with a reduced risk of hospitalizations (aHR 0.77; 95% CI 0.71, 0.83; P < 0.001). In ULT initiators, attainment of a serum urate <360 micromol/l within 12 months of initiation associated with a reduced risk of hospitalizations (aHR 0.57; 95% CI 0.49, 0.67; P < 0.001) when compared with people initiating ULT but not attaining this target. CONCLUSION ULT associates with an increased risk of hospitalizations within the first 6 months of initiation but reduces hospitalizations in the long term, particularly when serum urate targets are achieved.
Collapse
Affiliation(s)
- Mark D Russell
- Correspondence to: Mark D. Russell, Centre for Rheumatic Diseases, Weston Education Centre, King’s College London, 10 Cutcombe Road, London SE5 9RJ, UK. E-mail:
| | | | - Andrew I Rutherford
- Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
| | - Benjamin Ellis
- Department of Rheumatology, Imperial College Healthcare NHS Foundation Trust, London, UK
| | - Sam Norton
- Centre for Rheumatic Diseases, King’s College London, London, UK
| | - Abdel Douiri
- School of Population Health and Environmental Sciences, King’s College London, London, UK
| | - Martin C Gulliford
- School of Population Health and Environmental Sciences, King’s College London, London, UK
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King’s College London, London, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King’s College London, London, UK
| |
Collapse
|
5
|
Russell MD, Galloway JB, Andrews CD, MacKenna B, Goldacre B, Mehrkar A, Curtis HJ, Butler-Cole B, O'Dwyer T, Qureshi S, Ledingham JM, Mahto A, Rutherford AI, Adas MA, Alveyn E, Norton S, Cope AP, Bechman K. Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY. Lancet Rheumatol 2022; 4:e853-e863. [PMID: 36447940 PMCID: PMC9691150 DOI: 10.1016/s2665-9913(22)00305-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Background The impact of the COVID-19 pandemic on the incidence and management of inflammatory arthritis is not understood. Routinely captured data in secure platforms, such as OpenSAFELY, offer unique opportunities to understand how care for patients with inflammatory arthritis was impacted upon by the pandemic. Our objective was to use OpenSAFELY to assess the effects of the pandemic on diagnostic incidence and care delivery for inflammatory arthritis in England and to replicate key metrics from the National Early Inflammatory Arthritis Audit. Methods In this population-level cohort study, we used primary care and hospital data for 17·7 million adults registered with general practices using TPP health record software, to explore the following outcomes between April 1, 2019, and March 31, 2022: (1) incidence of inflammatory arthritis diagnoses (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and undifferentiated inflammatory arthritis) recorded in primary care; (2) time to first rheumatology assessment; (3) time to first prescription of a disease-modifying antirheumatic drug (DMARD) in primary care; and (4) choice of first DMARD. Findings Among 17 683 500 adults, there were 31 280 incident inflammatory arthritis diagnoses recorded between April 1, 2019, and March 31, 2022. The mean age of diagnosed patients was 55·4 years (SD 16·6), 18 615 (59·5%) were female, 12 665 (40·5%) were male, and 22 925 (88·3%) of 25 960 with available ethnicity data were White. New inflammatory arthritis diagnoses decreased by 20·3% in the year commencing April, 2020, relative to the preceding year (5·1 vs 6·4 diagnoses per 10 000 adults). The median time to first rheumatology assessment was shorter during the pandemic (18 days; IQR 8-35) than before (21 days; 9-41). The proportion of patients prescribed DMARDs in primary care was similar before and during the pandemic; however, during the pandemic, fewer people were prescribed methotrexate or leflunomide, and more were prescribed sulfasalazine or hydroxychloroquine. Interpretation Inflammatory arthritis diagnoses decreased markedly during the early phase of the pandemic. The impact on rheumatology assessment times and DMARD prescribing in primary care was less marked than might have been anticipated. This study demonstrates the feasibility of using routinely captured, near real-time data in the secure OpenSAFELY platform to benchmark care quality on a national scale, without the need for manual data collection. Funding None.
Collapse
Affiliation(s)
- Mark D Russell
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Colm D Andrews
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Brian MacKenna
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Ben Goldacre
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Amir Mehrkar
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Helen J Curtis
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Ben Butler-Cole
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Thomas O'Dwyer
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Sumera Qureshi
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Joanna M Ledingham
- Rheumatology Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
| | - Arti Mahto
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK
| | - Andrew I Rutherford
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK
| | - Maryam A Adas
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Edward Alveyn
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Katie Bechman
- Centre for Rheumatic Diseases, King's College London, London, UK
| |
Collapse
|
6
|
Russell MD, Rutherford AI, Ellis B, Norton S, Douiri A, Gulliford MC, Cope AP, Galloway JB. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. Lancet Reg Health Eur 2022; 18:100416. [PMID: 35814340 PMCID: PMC9257653 DOI: 10.1016/j.lanepe.2022.100416] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Background Following studies reporting sub-optimal gout management, European (EULAR) and British (BSR) guidelines were updated to encourage the prescription of urate-lowering therapy (ULT) with a treat-to-target approach. We investigated whether ULT initiation and urate target attainment has improved following publication of these guidelines, and assessed predictors of these outcomes. Methods We used the Clinical Practice Research Datalink to assess attainment of the following outcomes in people (n = 129,972) with index gout diagnoses in the UK from 2004-2020: i) initiation of ULT; ii) serum urate ≤360 µmol/L and ≤300 µmol/L; iii) treat-to-target urate monitoring. Interrupted time-series analyses were used to compare trends in outcomes before and after updated EULAR and BSR management guidelines, published in 2016 and 2017, respectively. Predictors of ULT initiation and urate target attainment were modelled using logistic regression and Cox proportional hazards. Findings 37,529 (28.9%) of 129,972 people with newly-diagnosed gout had ULT initiated within 12 months. ULT initiation improved modestly over the study period, from 26.8% for those diagnosed in 2004 to 36.6% in 2019 and 34.7% in 2020. Of people diagnosed in 2020 with a serum urate performed within 12 months, 17.1% attained a urate ≤300 µmol/L, while 36.0% attained a urate ≤360 µmol/L. 18.9% received treat-to-target urate monitoring. No significant improvements in ULT initiation or urate target attainment were observed after updated BSR or EULAR management guidance, relative to before. Comorbidities, including chronic kidney disease (CKD), heart failure and obesity, and diuretic use associated with increased odds of ULT initiation but decreased odds of attaining urate targets within 12 months: CKD (adjusted OR 1.61 for ULT initiation, 95% CI 1.55 to 1.67; adjusted OR 0.51 for urate ≤300 µmol/L, 95% CI 0.48 to 0.55; both p < 0.001); heart failure (adjusted OR 1.56 for ULT initiation, 95% CI 1.48 to 1.64; adjusted OR 0.85 for urate ≤300 µmol/L, 95% CI 0.76 to 0.95; both p < 0.001); obesity (adjusted OR 1.32 for ULT initiation, 95% CI 1.29 to 1.36; adjusted OR 0.61 for urate ≤300 µmol/L, 95% CI 0.58 to 0.65; both p < 0.001); and diuretic use (adjusted OR 1.49 for ULT initiation, 95% CI 1.44 to 1.55; adjusted OR 0.61 for urate ≤300 µmol/L, 95% CI 0.57 to 0.66; both p < 0.001). Interpretation Initiation of ULT and attainment of urate targets remain poor for people diagnosed with gout in the UK, despite updated management guidelines. If the evidence-practice gap in gout management is to be bridged, strategies to implement best practice care are needed. Funding National Institute for Health Research.
Collapse
Affiliation(s)
- Mark D Russell
- Centre for Rheumatic Diseases, King's College London, SE5 9RJ, UK
- Corresponding author at: Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London, SE5 9RJ, UK.
| | - Andrew I Rutherford
- Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, SE5 9RS, UK
| | - Benjamin Ellis
- Department of Rheumatology, Imperial College Healthcare NHS Foundation Trust, London
| | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, SE5 9RJ, UK
| | - Abdel Douiri
- School of Population Health and Environmental Sciences, King's College London, SE1 1UL, UK
| | - Martin C Gulliford
- School of Population Health and Environmental Sciences, King's College London, SE1 1UL, UK
| | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, SE5 9RJ, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, SE5 9RJ, UK
| |
Collapse
|
7
|
Russell MD, Nagra D, Clarke BD, Balachandran S, Buazon A, Boalch A, Bechman K, Adas MA, Alveyn EG, Rutherford AI, Galloway JB. Hospitalizations for acute gout: process mapping the inpatient journey and identifying predictors of admission. J Rheumatol 2022; 49:725-730. [DOI: 10.3899/jrheum.211203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/02/2022] [Indexed: 11/22/2022]
Abstract
Objective To identify predictors of admission following emergency attendances for gout flares, and describe barriers to optimal inpatient gout care. Methods Emergency department (ED) attendances and hospital admissions with primary diagnoses of gout were analyzed at two UK-based hospitals between 1st January 2017 and 31st December 2020. Demographic and clinical predictors of ED disposition (admission or discharge) and re-attendance for gout flares were identified using logistic regression and survival models, respectively. Case-note reviews (n=59), stakeholder meetings and process mapping were performed to capture detailed information on gout management and identify strategies to optimize care. Results Of 1,220 emergency attendances for gout flares, 23.5% required hospitalization (median length of stay: 3.6 days). Recurrent attendances for flares occurred in 10.4% of patients during the study period. In multivariate logistic regression models, significant predictors of admission from ED were older age, overnight ED arrival time, higher serum urate, higher CRP and higher total white cell count at presentation. Detailed case-note reviews showed that only 22.6% of patients with pre-existing gout were receiving urate-lowering therapy (ULT) at presentation. Initial diagnostic uncertainty was common, yet rheumatology input and synovial aspirates were rarely obtained. By six months post-discharge, 43.6% were receiving ULT; however, few patients had treat-to-target dose optimization, and only 9.1% achieved a urate ≤360 micromol/L. Conclusion We identified multiple predictors of hospitalization for acute gout. Prescription of ULT and treat-to-target optimization following hospitalization remain inadequate, and must be improved if admissions are to be prevented.
Collapse
|
8
|
Adas MA, Allen VB, Yates M, Bechman K, Clarke BD, Russell MD, Rutherford AI, Cope AP, Norton S, Galloway JB. A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis. Rheumatology (Oxford) 2021; 60:4450-4462. [PMID: 34003970 PMCID: PMC8487311 DOI: 10.1093/rheumatology/keab429] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 04/29/2021] [Accepted: 05/06/2021] [Indexed: 11/18/2022] Open
Abstract
Objectives To evaluate the safety of treatment strategies in patients with early RA. Methods Systematic searches of MEDLINE, EMBASE and PubMed were conducted up to September 2020. Double-blind randomized controlled trials (RCTs) of licensed treatments conducted on completely naïve or MTX-naïve RA patients were included. Long-term extension studies, post-hoc and pooled analyses and RCTs with no comparator arm were excluded. Serious adverse events, serious infections and non-serious adverse events were extracted from all RCTs, and event rates in intervention and comparator arms were compared using meta-analysis and network meta-analysis (NMA). Results From an initial search of 3423 studies, 20 were included, involving 9202 patients. From the meta-analysis, the pooled incidence rates per 1000 patient-years for serious adverse events were 69.8 (95% CI: 64.9, 74.8), serious infections 18.9 (95% CI: 16.2, 21.6) and non-serious adverse events 1048.2 (95% CI: 1027.5, 1068.9). NMA showed that serious adverse event rates were higher with biologic monotherapy than with MTX monotherapy, rate ratio 1.39 (95% CI: 1.12, 1.73). Biologic monotherapy rates were higher than those for MTX and steroid therapy, rate ratio 3.22 (95% CI: 1.47, 7.07). Biologic monotherapy had a higher adverse event rate than biologic combination therapy, rate ratio 1.26 (95% CI: 1.02, 1.54). NMA showed no significant difference between strategies with respect to serious infections and non-serious adverse events rates. Conclusion The study revealed the different risk profiles for various early RA treatment strategies. Observed differences were overall small, and in contrast to the findings of established RA studies, steroid-based regimens did not emerge as more harmful.
Collapse
Affiliation(s)
- Maryam A Adas
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Victoria B Allen
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Mark Yates
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Katie Bechman
- Centre for Rheumatic Diseases, King's College London, London, UK
| | | | - Mark D Russell
- Centre for Rheumatic Diseases, King's College London, London, UK
| | | | - Andrew P Cope
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - Sam Norton
- Centre for Rheumatic Diseases, King's College London, London, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK
| |
Collapse
|
9
|
Nagra D, Russell MD, Rosmini S, Sado D, Buazon A, Shafi T, Hamlyn E, Sandhu G, Rutherford AI, Galloway JB. A Kawasaki-like illness in an adult with recent SARS-CoV-2 infection. Rheumatol Adv Pract 2021; 5:rkab035. [PMID: 34159291 PMCID: PMC8194598 DOI: 10.1093/rap/rkab035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 05/10/2021] [Indexed: 01/09/2023] Open
Affiliation(s)
- Deepak Nagra
- Centre for Rheumatic Disease, King's College London
| | | | | | - Daniel Sado
- King's College Hospital NHS Foundation Trust, London, UK
| | - April Buazon
- Centre for Rheumatic Disease, King's College London
| | - Taimur Shafi
- King's College Hospital NHS Foundation Trust, London, UK
| | | | | | | | | |
Collapse
|
10
|
Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, Bechman K, Clarke BD, Nagra D, Norton S, Russell MD, Rutherford AI, Yates M, Galloway JB. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J Infect 2021; 82:178-185. [PMID: 33745918 PMCID: PMC7970418 DOI: 10.1016/j.jinf.2021.03.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Accepted: 03/13/2021] [Indexed: 12/29/2022]
Abstract
Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been published, with conflicting conclusions. We performed a meta-analysis to assess the impact of IL-6 inhibition on mortality from COVID-19, utilising meta-regression to explore differences in study results. Methods Systematic database searches were performed to identify RCTs comparing IL-6 inhibitors (tocilizumab and sarilumab) to placebo or standard of care in adults with COVID-19. Meta-analysis was used to estimate the relative risk of mortality at 28 days between arms, expressed as a risk ratio. Within-study mortality rates were compared, and meta-regression was used to investigate treatment effect modification. Results Data from nine RCTs were included. The combined mortality rate across studies was 19% (95% CI: 18, 20%), ranging from 2% to 31%. The overall risk ratio for 28-day mortality was 0.90 (95% CI: 0.81, 0.99), in favour of benefit for IL-6 inhibition over placebo or standard of care, with low treatment effect heterogeneity: I2 0% (95% CI: 0, 53%). Meta-regression showed no evidence of treatment effect modification by patient characteristics. Trial-specific mortality rates were explained by known patient-level predictors of COVID-19 outcome (male sex, CRP, hypertension), and country-level COVID-19 incidence. Conclusions IL-6 inhibition is associated with clinically meaningful improvements in outcomes for patients admitted with COVID-19. Long-term benefits of IL-6 inhibition, its effectiveness across healthcare systems, and implications for differing standards of care are currently unknown.
Collapse
Affiliation(s)
- Emmanuel Tharmarajah
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - April Buazon
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Vishit Patel
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Jennifer R Hannah
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Maryam Adas
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Victoria B Allen
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Katie Bechman
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Benjamin D Clarke
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Deepak Nagra
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Sam Norton
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Mark D Russell
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK.
| | - Andrew I Rutherford
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - Mark Yates
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| | - James B Galloway
- Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK
| |
Collapse
|
11
|
Russell MD, Yates M, Bechman K, Rutherford AI, Subesinghe S, Lanyon P, Galloway JB. Rising Incidence of Acute Hospital Admissions due to Gout. J Rheumatol 2019; 47:619-623. [DOI: 10.3899/jrheum.190257] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2019] [Indexed: 01/10/2023]
Abstract
Objective.To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications.Methods.An ecological study was performed using UK National Health Service (NHS) Digital Hospital Episode Statistics data to calculate the incidence of unplanned admissions with primary diagnoses of gout or RA in adults in England between April 2006 and March 2017. NHS Digital Community Prescription data for allopurinol, febuxostat, and colchicine were considered over a similar period.Results.The incidence of unplanned gout admissions increased by 58.4% over the study period, from 7.9 admissions per 100,000 population in 2006/07 to 12.5 admissions per 100,000 population in 2016/17 (p < 0.0001). Gout admissions increased as a proportion of all hospital admissions, and accounted for 349,768 bed-days cumulatively. Unplanned RA admissions halved over the study period, from 8.6 admissions per 100,000 population in 2006/07 to 4.3 admissions per 100,000 population in 2016/17 (p < 0.0001). Community prescriptions dispensed for allopurinol and colchicine have increased by 71.4% and 165.6%, respectively, since 2006 (p < 0.0001). Febuxostat prescriptions have increased 20-fold since 2010 (p < 0.0001), when prescription data became available.Conclusion.Acute gout admissions in England increased between 2006 and 2017, accompanied by increasing prescription of gout therapies. Acute admissions due to RA halved over the same time period. These data call for aggressive target-driven therapy for this highly treatable disease.
Collapse
|
12
|
Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2019; 58:1767-1776. [DOI: 10.1093/rheumatology/kez037] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Accepted: 01/12/2019] [Indexed: 01/23/2023] Open
Abstract
Abstract
Objective
To evaluate whether polypharmacy is associated with treatment response and serious adverse events (SAEs) in patients with RA using data from the British Society for Rheumatology Biologics Register (BSRBR-RA).
Methods
The BSRBR-RA is a prospective observational cohort study of biologic therapy starters and a DMARD comparator arm. A logistic regression model was used to calculate the odds of a EULAR ‘good response’ after 12 months of biologic therapy by medication count. Cox proportional hazards models were used to identify risk of SAEs. The utility of the models were compared with the Rheumatic Disease Comorbidity Index using Receiver Operator Characteristic and Harrell’s C statistic.
Results
The analysis included 22 005 patients, of which 83% were initiated on biologics. Each additional medication reduced the odds of a EULAR good response by 8% [odds ratios 0.92 (95% CI 0.91, 0.93) P < 0.001] and 3% in the adjusted model [adjusted odds ratios 0.97 (95% CI 0.95, 0.98) P < 0.001]. The Receiver Operator Characteristic demonstrated significantly greater areas under the curve with the polypharmacy model than the Rheumatic Disease Comorbidity Index. There were 12 547 SAEs reported in 7286 patients. Each additional medication equated to a 13% increased risk of an SAE [hazard ratio 1.13 (95% CI 1.12, 1.13) P < 0.001] and 6% in the adjusted model [adjusted hazard ratio 1.06 (95% CI 1.05, 1.07) P < 0.001]. Predictive values for SAEs were comparable between the polypharmacy and Rheumatic Disease Comorbidity Index model.
Conclusion
Polypharmacy is a simple but valuable predictor of clinical outcomes in patients with RA. This study supports medication count as a valid measure for use in epidemiologic analyses.
Collapse
Affiliation(s)
- Katie Bechman
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Benjamin D Clarke
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Andrew I Rutherford
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Mark Yates
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Elena Nikiphorou
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Mariam Molokhia
- Primary Care & Public Health Sciences, Health & Social Care Research, Kings College London, London
| | - Sam Norton
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Andrew P Cope
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| | - Kimme L Hyrich
- Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, University of Manchester
- NIHR Manchester Biomedical Research Centre, Manchester Foundation Trust, Manchester, UK
| | - James B Galloway
- Department of Inflammation Biology, School of Immunology & Microbial Sciences
| |
Collapse
|
13
|
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2018. [PMID: 29529307 DOI: 10.1093/rheumatology/key023] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Objectives This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. Methods The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately. Results In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs. Conclusions The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
Collapse
Affiliation(s)
- Andrew I Rutherford
- Academic Rheumatology Department, King's College London, London, UK.,Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK
| | - Eunice Patarata
- Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK.,Autoimmune Disease Unit, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, UK
| | | | - Kimme L Hyrich
- Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester University, Manchester, UK.,NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester Foundation Trust, Manchester, UK
| | - James B Galloway
- Academic Rheumatology Department, King's College London, London, UK.,Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
14
|
Bechman K, Rutherford AI, Subesinghe S, Russell MD, Yates M, Norton S, Galloway J. 230 Liver function abnormalities on conventional DMARDs: results from a contemporary cohort. Rheumatology (Oxford) 2018. [DOI: 10.1093/rheumatology/key075.454] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Katie Bechman
- Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | | | - Sujith Subesinghe
- Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Mark D Russell
- Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Mark Yates
- Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Sam Norton
- Academic Rheumatology and Health Psychology Department, King's College London, London, UNITED KINGDOM
| | - James Galloway
- Academic Rheumatology, King's College London, London, UNITED KINGDOM
| |
Collapse
|
15
|
Russell MD, Yates M, Rutherford AI, Subesinghe S, Bechman K, Lanyon P, Galloway JB. O04 Return of the king: rising incidence of gout in England 2006-2017 (Young investigator award winner 2018). Rheumatology (Oxford) 2018. [DOI: 10.1093/rheumatology/key075.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Mark D Russell
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Mark Yates
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Andrew I Rutherford
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Sujith Subesinghe
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Katie Bechman
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| | - Peter Lanyon
- Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UNITED KINGDOM
| | - James B Galloway
- Department of Academic Rheumatology, King's College London, London, UNITED KINGDOM
| |
Collapse
|
16
|
Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77:905-910. [PMID: 29592917 DOI: 10.1136/annrheumdis-2017-212825] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2017] [Accepted: 03/16/2018] [Indexed: 11/03/2022]
Abstract
OBJECTIVES To compare the incidence of serious infection (SI) across biologic drugs used to treat rheumatoid arthritis (RA) using data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). METHODS The BSRBR-RA is a prospective observational cohort study. This analysis included patients with RA starting a new biologic. The primary outcome was SI defined as an infectious event requiring admission to hospital, intravenous antibiotics or resulting in death. Event rates were calculated and compared across biologics using Cox proportional hazards with adjustment for potential confounders. Secondary outcomes were the rate of infection by organ class and 30-day mortality following infection. RESULTS This analysis included 19 282 patients with 46 771 years of follow-up. The incidence of SI was 5.51 cases per 100 patient years for the entire cohort (95% CI 5.29 to 5.71). Compared with etanercept, tocilizumab had a higher risk of SI (HR 1.22, 95% CI 1.02 to 1.47) and certolizumab pegol a lower risk of SI (HR 0.75, 95% CI 0.58 to 0.97) in the fully adjusted model. The 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). CONCLUSIONS The rate of SI was lower with certolizumab pegol than etanercept in the primary analysis but the result was no longer significant in several sensitivity analyses performed suggesting residual confounding may account for the observed difference. From these results, it would be wrong to conclude that certolizumab pegol has a lower rate of SI than other biologics; however, the risk does not appear to be significantly higher as has previously been suggested.
Collapse
Affiliation(s)
- Andrew I Rutherford
- Academic Rheumatology Department, King's College London, London, UK.,Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK
| | | | - Kimme L Hyrich
- Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester University, Manchester, UK.,NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester Foundation Trust, Manchester, UK
| | - James B Galloway
- Academic Rheumatology Department, King's College London, London, UK.,Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
17
|
Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45:733-744. [PMID: 29545454 DOI: 10.3899/jrheum.170710] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/15/2017] [Indexed: 01/25/2023]
Abstract
OBJECTIVE Vaccination is a key strategy to reduce infection risk in patients with rheumatoid arthritis (RA) and is advocated in internationally recognized rheumatology society guidelines. The aim was to evaluate to the effect of antirheumatic drugs on influenza and pneumococcal vaccine immunogenicity. METHODS We conducted a systematic literature review and metaanalysis comparing the humoral response to influenza (pandemic and seasonal trivalent subunit vaccines) and pneumococcal (23-valent pneumococcal polysaccharide vaccine, 7- and 13-valent pneumococcal conjugated vaccines) vaccination in adult patients with RA treated with antirheumatic drugs. Vaccine immunogenicity was assessed by seroprotection rates measured 3 to 6 weeks postimmunization. Risk ratios (RR) and 95% CI were pooled. RESULTS Nine studies were included in the metaanalysis (7 studies investigating antirheumatic drug exposures and influenza humoral response, 2 studies investigating pneumococcal vaccine response). Influenza vaccine responses to all subunit strains (H1N1, H3N2, B strain) were preserved with methotrexate (MTX) and tumor necrosis factor inhibitor (TNFi) drug exposure. MTX but not TNFi drug exposure was associated with reduced 6B and 23F serotype pneumococcal vaccine response (RR 0.42, 95% CI 0.28-0.63 vs RR 0.98, 95% CI 0.58-1.67); however, limited data were available to draw any firm conclusions. Combination of MTX with tocilizumab or tofacitinib was associated with reduced pneumococcal and influenza vaccine responses. CONCLUSION Antirheumatic drugs may limit humoral responses to vaccination as evidenced by pneumococcal responses with MTX exposure; however, they are safe and should not preclude immunization against vaccine-preventable disease. Vaccination should be considered in all patients with RA and encouraged as part of routine care. (Systematic review registration number: PROSPERO 2016: CRD42016048093.).
Collapse
Affiliation(s)
- Sujith Subesinghe
- From the Department of Academic Rheumatology, King's College London, Weston Education Centre; Institute of Child Health, University College London, London, UK. .,S. Subesinghe, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; K. Bechman, BSc, MBBS, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; A.I. Rutherford, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; D. Goldblatt, MBChB, FRCPCH, FRCP, PhD, Prof, Vaccinology and Immunology, Institute of Child Health, University College London; J.B. Galloway, MBChB, MSc, CHP, FRCP, PhD, FAcadMedEd, Senior Lecturer and Honorary Consultant Rheumatologist, Department of Academic Rheumatology, King's College London, Weston Education Centre.
| | - Katie Bechman
- From the Department of Academic Rheumatology, King's College London, Weston Education Centre; Institute of Child Health, University College London, London, UK.,S. Subesinghe, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; K. Bechman, BSc, MBBS, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; A.I. Rutherford, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; D. Goldblatt, MBChB, FRCPCH, FRCP, PhD, Prof, Vaccinology and Immunology, Institute of Child Health, University College London; J.B. Galloway, MBChB, MSc, CHP, FRCP, PhD, FAcadMedEd, Senior Lecturer and Honorary Consultant Rheumatologist, Department of Academic Rheumatology, King's College London, Weston Education Centre
| | - Andrew I Rutherford
- From the Department of Academic Rheumatology, King's College London, Weston Education Centre; Institute of Child Health, University College London, London, UK.,S. Subesinghe, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; K. Bechman, BSc, MBBS, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; A.I. Rutherford, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; D. Goldblatt, MBChB, FRCPCH, FRCP, PhD, Prof, Vaccinology and Immunology, Institute of Child Health, University College London; J.B. Galloway, MBChB, MSc, CHP, FRCP, PhD, FAcadMedEd, Senior Lecturer and Honorary Consultant Rheumatologist, Department of Academic Rheumatology, King's College London, Weston Education Centre
| | - David Goldblatt
- From the Department of Academic Rheumatology, King's College London, Weston Education Centre; Institute of Child Health, University College London, London, UK.,S. Subesinghe, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; K. Bechman, BSc, MBBS, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; A.I. Rutherford, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; D. Goldblatt, MBChB, FRCPCH, FRCP, PhD, Prof, Vaccinology and Immunology, Institute of Child Health, University College London; J.B. Galloway, MBChB, MSc, CHP, FRCP, PhD, FAcadMedEd, Senior Lecturer and Honorary Consultant Rheumatologist, Department of Academic Rheumatology, King's College London, Weston Education Centre
| | - James B Galloway
- From the Department of Academic Rheumatology, King's College London, Weston Education Centre; Institute of Child Health, University College London, London, UK.,S. Subesinghe, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; K. Bechman, BSc, MBBS, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; A.I. Rutherford, BSc, MBBS, MSc, MRCP, Clinical Research Fellow and Rheumatology Registrar, Department of Academic Rheumatology, King's College London, Weston Education Centre; D. Goldblatt, MBChB, FRCPCH, FRCP, PhD, Prof, Vaccinology and Immunology, Institute of Child Health, University College London; J.B. Galloway, MBChB, MSc, CHP, FRCP, PhD, FAcadMedEd, Senior Lecturer and Honorary Consultant Rheumatologist, Department of Academic Rheumatology, King's College London, Weston Education Centre
| |
Collapse
|
18
|
Houssien AD, Rutherford AI, Yates M, Galloway J. 169. PREDICTORS OF WORK DISABILITY IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW. Rheumatology (Oxford) 2017. [DOI: 10.1093/rheumatology/kex062.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. 145. OPPORTUNISTIC INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS EXPOSED TO BIOLOGIC THERAPY: UPDATED RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER. Rheumatology (Oxford) 2017. [DOI: 10.1093/rheumatology/kex062.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Rutherford AI, Subesinghe S, Bharucha T, Ibrahim F, Kleymann A, Galloway JB. A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013. Rheumatology (Oxford) 2016; 55:2176-2180. [DOI: 10.1093/rheumatology/kew323] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 06/28/2016] [Indexed: 11/13/2022] Open
|
21
|
|